Fish Oil for Type 2 Diabetes
(END-T2D Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this clinical trial is to find out whether one type of fish oil works better than another at improving metabolic health in people who are at high risk of developing type 2 diabetes.
Some metabolic problems-such as difficulty controlling blood sugar, unhealthy particles that transport cholesterol in the blood, and poor fat tissue function-can increase the risk of type 2 diabetes. This study aims to determine whether different types of fish oil can:
1. Improve how well the body produces insulin and responds to it,
2. Improve the quality of the particles that carry "bad" cholesterol in the blood, and 3) Improve the health and function of participants' fat tissue.
To answer these questions, researchers will compare the effects of two types of fish oil: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). These will be compared with corn oil, which is used as a placebo and does not contain EPA or DHA.
When included in this study, participants will:
A) Take softgel capsules containing EPA, DHA, or placebo (corn oil) every day for 12 weeks, B) Keep a daily log to record when they take their study softgels, and C) Visit the research unit six times, including one and a half days before and after the intervention, to complete specialized metabolic tests that are mostly only available in research settings.
Who Is on the Research Team?
May Faraj, P.Dt., Ph.D.
Principal Investigator
Institut de recherches cliniques de Montréal (IRCM)/ Université de Montréal
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo specialized metabolic testing to assess glucose processing and fat tissue response
Treatment
Participants take softgel capsules containing EPA, DHA, or placebo daily for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
3
Treatment groups
Active Control
Placebo Group
Four softgels of Carlson Elite DHA Gems (NPN 80079736) providing 4 g DHA per day
Four softgels of Carlson Elite EPA Gems (NPN 80079735) providing 4 g EPA per day
Four softgels of Carlson placebo softgels providing 0 g EPA and DHA per day
Find a Clinic Near You
Who Is Running the Clinical Trial?
May Faraj, PDt, PhD
Lead Sponsor
Diabetes Canada
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.